醫美板塊走強 愛美客大漲近9%
格隆匯3月30日丨醫美板塊企穩反攻,愛美客大漲近9%,朗姿股份漲超5%,華熙生物漲超4%,華東醫藥、昊海生科等跟漲。中信建投證券研報指,中國是全球第二大醫美市場,據預測2023年有望超越美國成為全球最大醫美市場。預測2024年我國醫美市場規模有望突破3000億元,相比於2019年市場翻倍增長。綜合對比國內外醫美滲透率和消費金額等指標,中長期看我國醫美行業仍有5倍以上成長空間。如果考慮到我國合規機構僅佔14%,真實醫美市場規模可達萬億級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.